Shenzhen Herz Life Science Technology Co., Ltd. was founded in March 2020 by scientists returning from Europe, with its headquarters located in Guangming District, Shenzhen.The company has established a proprietary fourth-generation novel vaccine technology platform. Compared with traditional vaccines, this technology delivers higher safety and stronger immunogenicity, and supports the development of vaccines targeting endogenous antigens.

Leveraging this platform, the company is developing multiple innovative vaccines including a feline contraceptive vaccine and a feline infectious peritonitis (FIP) vaccine. As the world’s first pet contraceptive vaccine, the feline contraceptive vaccine is undergoing new veterinary drug registration applications in China and overseas jurisdictions simultaneously.

The firm operates a roughly 4,000 m² R&D facility and a 6,000 m² pilot-scale production base. It has filed 53 patents in China and under the PCT system, of which 14 have been granted.Since 2021, the company has completed multiple rounds of financing totaling several hundred million yuan from investors including Qinzhi Capital, Tongchuang Weiye, Innovent Biologics and Northern Light Venture Capital.